Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Conclusion

- 13/10/20 - 1 formulario, 4 itemgroups, 9 items, 1 idioma

Itemgroups: Date of visit, Assessment Date, Cessation of life, Pregnancy, Information, Conclusion, Clinical Research

Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases

Bladder Cancer NCT01224665 Off Treatment - S1011 Notice of Death Form (#49467) - 3152396v1.0 - S1011 Notice of Death Form (#49467)

- 9/1/15 - 1 formulario, 4 itemgroups, 22 items, 1 idioma

Itemgroups: Header Module, Date of Death, CAUSES OF DEATH, Comments

S1011 Notice of Death Form (#49467) Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9339E952-BBCA-996A-E040-BB89AD43480C

Effects of Esomeprazole on Lapatinib in Subjects with Breast Cancer; 109275 - Follow-up

- 25/6/20 - 1 formulario, 10 itemgroups, 187 items, 1 idioma

Itemgroups: Date of visit, Vital signs, 12 lead ECG, 12 lead ECG, Abnormality, Experimental drug, Continuation status, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Hematology finding, Conclusion, Clinical Research, Cessation of life, Pregnancy, Information

Study ID: 109275 Clinical Study ID: 109275 Study Title: An Open-Label, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects with Metastatic ErbB2 Positive Breast Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Lapatinib, Esomeprazole Trade Name: lapatinib plus esomeprazole Study Indication: Neoplasms, Breast

Death Form (F04) Brain and Central Nervous System Tumors (NCT00890747)

- 8/1/15 - 1 formulario, 1 itemgroup, 10 items, 1 idioma

Itemgroup: Death Information

AMC-061 Death Form (F04) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy NCT00890747 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=71988CF7-F80D-68F0-E040-BB89AD4358A1

S0337 Notice of Death NCT00445601

- 5/7/15 - 1 formulario, 4 itemgroups, 22 items, 1 idioma

Itemgroups: Header, Date of death, CAUSES OF DEATH, Comments

S0337 Notice of Death NCT00445601 Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FE24F40B-3D03-490A-E034-0003BA3F9857

ADVL0212: Death Worksheet NCT00053963

- 8/7/15 - 1 formulario, 3 itemgroups, 14 items, 1 idioma

Itemgroups: Header, Death Assessment, CCRR MODULE

ADVL0212: Death Worksheet NCT00053963 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1EAD089-F0A7-3073-E034-0003BA12F5E7

HYCAMTIN in Combination With Carboplatin in Subjects with Ovarian Cancer; NCT00316173 - Death

- 12/7/19 - 1 formulario, 2 itemgroups, 4 items, 1 idioma

Itemgroups: Administrative documentation, Cessation of life

Study ID: 104864/902 Clinical Study ID: 104864/902 Study Title: An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 Every 21 Days) HYCAMTIN in Combination With Carboplatin (Day 1 Every 21 Days) as Second-Line Therapy in Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00316173 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: CARBOPLATIN Study Indication: Ovarian Cancer; Neoplasms, Ovarian

SIOP CNS GCT II Death of patient DRKS00003907 - Death of patient

- 19/9/14 - 1 formulario, 2 itemgroups, 5 items, 2 idiomas

Itemgroups: Show identification of patient, Death of patient

SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Intracranial Germ Cell Tumors. Principal Investigator Gabriele Calaminus, MD. http://clinicaltrials.gov/show/NCT01424839

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Survival Information; Form D; Termination Record

- 3/9/19 - 1 formulario, 9 itemgroups, 29 items, 1 idioma

Itemgroups: Survival Information - Month of Report, Survival Information - Review of disease status, Survival Information - Outcome, Form D, Termination Record, Termination Record - Review of Disease Status, Termination Record - Best Overall Response, Termination Record - Study Conclusion, Termination Record - Investigator Signature

Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

IBCSG Long Term Follow-Up Death Form (18-LTF-Death)

- 12/6/17 - 1 formulario, 3 itemgroups, 12 items, 1 idioma

Itemgroups: Header Module, LONG TERM FOLLOW-UP, Footer Module

IBCSG Long Term Follow-Up Death Form (18-LTF-Death) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=889C3F60-2C95-8540-E040-BB89AD4303DD

Palabras clave

Tabla de contenido

Modelos de datos seleccionados